Ion Beam Applications SA IBA (GB:0GZK) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
PanTera, a joint venture of IBA (Ion Beam Applications S.A), has raised EUR 93 million in an oversubscribed Series A funding round, led by EQT Life Sciences, to accelerate the production of actinium-225, a critical component for new targeted cancer treatments. The financing, which is the largest Series A in Belgium’s life sciences sector, brings the total raised to EUR 134 million and will support the construction of a new production facility. With IBA’s participation reducing to 31.3%, the transaction will positively impact IBA’s profits by approximately EUR 23 million over the next three years.
For further insights into GB:0GZK stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money